Title (en)

PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS

Title (de)

VERFAHREN ZUR HERSTELLUNG VON CALCIUMSALZFORMEN VON STATINEN

Title (fr)

PROCEDES PERMETTANT DE PREPARER DES FORMES SALINES CALCIQUES DE STATINES

Publication

EP 1425287 A4 20050907 (EN)

Application

EP 02759374 A 20020816

Priority

- US 0226012 W 20020816
- US 31281201 P 20010816
- US 3741201 A 20011024

Abstract (en)

[origin: WO03016317A1] Processes for preparing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected satin ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide.

IPC 1-7

C07D 207/24; C07C 51/09; C07D 209/24; C07D 213/55; C07D 215/14; C07D 239/42; C07D 309/30; A61K 31/22; A61K 31/40; A61K 31/47; A61K 31/351; A61K 31/404; A61K 31/4418; A61K 31/4965; A61P 9/00

IPC 8 full level

A61K 31/22 (2006.01); **A61K 31/351** (2006.01); **A61K 31/40** (2006.01); **A61K 31/404** (2006.01); **A61K 31/4418** (2006.01); **A61K 31/47** (2006.01); **A61K 31/4965** (2006.01); **C07B 61/00** (2006.01); **C07C 69/013** (2006.01); **C07C 69/30** (2006.01); **C07D 207/34** (2006.01); **C07D 209/24** (2006.01); **C07D 213/55** (2006.01); **C07D 215/14** (2006.01); **C07D 239/42** (2006.01); **C07C 67/28** (2006.01); **C07D 309/30** (2006.01); **C07F 3/04** (2006.01)

CPC (source: EP)

A61P 3/06 (2018.01); **A61P 9/00** (2018.01); **A61P 9/10** (2018.01); **C07D 207/34** (2013.01); **C07D 209/24** (2013.01); **C07D 213/55** (2013.01); **C07D 215/14** (2013.01); **C07D 239/42** (2013.01); **C07D 309/30** (2013.01); Y02P 20/55 (2015.11)

Citation (search report)

- [X] US 4137322 A 19790130 - ENDO AKIRA, et al
- [PX] WO 0243667 A2 20020606 - TEVA PHARMA [IL], et al
- [PX] WO 0243732 A1 20020606 - TEVA PHARMA [IL], et al
- [PX] WO 02051804 A1 20020704 - CIBA SC HOLDING AG [CH], et al
- [E] WO 03018547 A2 20030306 - MOREPEN LAB LTD [IN], et al

Citation (examination)

- WO 0049014 A1 20000824 - ASTRAZENECA UK LTD [GB], et al
- WATANABE M ET AL: "Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY 199702 GB LNKD-DOI:10.1016/S0968-0896(96)00248-9, vol. 5, no. 2, February 1997 (1997-02-01), pages 437 - 444, ISSN: 0968-0896
- See also references of WO 03016317A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03016317 A1 20030227; AU 2002324715 B2 20090312; CA 2450820 A1 20030227; CA 2450820 C 20110315; CN 100430405 C 20081105; CN 1543468 A 20041103; CZ 2004337 A3 20050112; EP 1425287 A1 20040609; EP 1425287 A4 20050907; HR P20040255 A2 20040831; HR PK20040255 B3 20060228; HU P0500616 A2 20051128; HU P0500616 A3 20110728; IL 160077 A0 20040620; IL 160077 A 20071031; IS 7148 A 20040211; JP 2005500382 A 20050106; JP 2009024008 A 20090205; JP 4188826 B2 20081203; MX PA04001451 A 20050217; NO 20041082 L 20040315; NZ 529913 A 20050324; PL 370407 A1 20050530; SK 1402004 A3 20050103; TR 200302281 T2 20040921

DOCDB simple family (application)

US 0226012 W 20020816; AU 2002324715 A 20020816; CA 2450820 A 20020816; CN 02815999 A 20020816; CZ 2004337 A 20020816; EP 02759374 A 20020816; HR P20040255 A 20040315; HU P0500616 A 20020816; IL 16007702 A 20020816; IL 16007704 A 20040127; IS 7148 A 20040211; JP 2003521239 A 20020816; JP 2008184147 A 20080715; MX PA04001451 A 20020816; NO 20041082 A 20040315; NZ 52991302 A 20020816; PL 37040702 A 20020816; SK 1402004 A 20020816; TR 200302281 T 20020816